UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) 1222 Demonbreun Street, Suite 2000, ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Jessica Serra – Investor Relations Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Seamus Fernandez – Guggenheim Balaji Prasad – Barclays Chris Shibutani – Goldman Sachs Stacy Ku – Cowen David Amsellem – Piper Sandler Terence Flynn – Morgan Stanley Operator Welcome to the Revance Therapeutics First Quarter 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

Forward-Looking Statements | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------| | | | | | | | | REVANCE | | | | | | | Investor | | | | | | | Presentation | | | | | | | NASDAQ: RVNC | | | | | | | | | | | | | | March 2023 | | | | | | This presentation also contains estimates and other statistical data made by independent parties and by us relcling to nacket size and growth and other odata doubut our inc of assumptions and limitations, and you are coulioned not to give ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Company Participants Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Annabel Samimy – Stifel Seamus Fernandez – Guggenheim Securities Stacy Ku – Cowen Balaji Prasad – Barclays Lachlan Hanbury-Brown – William Blair Terence Flynn – Morgan Stanley ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ | Securities Registered Pursuant to Section 12(b) of the Act: | | | | --- | --- | --- | | Title of each class | Trading Symbol(s) | Name of eac ...

Call Start: 16:30 January 1, 0000 5:20 PM ET Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2022 Earnings Conference Call August 9, 2022 16:30 ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Seamus Fernandez - Guggenheim Partners Ken Cacciatore - Cowen Annabel Samimy - Stifel David Amsellem - Piper Sandler Tim Lugo - William B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...